Blood:感染新冠肺炎的多发性骨髓瘤患者的预后及相关危险因素

2020-12-30 MedSci原创 MedSci原创

在新冠肺炎病毒大流行期间,癌症是新冠肺炎死亡的主要危险因素之一。多发性骨髓瘤(MM)患者死亡的主要原因是并发感染。因此,感染新冠肺炎病毒的多发性骨髓瘤患者的预后备受关注。

新冠肺炎病毒大流行期间,癌症是新冠肺炎死亡的主要危险因素之一。多发性骨髓瘤(MM)患者死亡的主要原因是并发感染。因此,感染新冠肺炎病毒的多发性骨髓瘤患者的预后备受关注。

该研究回顾性描述了国际骨髓瘤协会收集的650例浆细胞疾病患者感染新冠肺炎病毒的基线特征和转归数据,以了解骨髓瘤患者在新冠肺炎病毒大流行期间面临的主要挑战

通过对住院治疗的浆细胞疾病患者进行分析发现,在住院患者(中位年龄69岁)中,几乎所有患者(96%)都是多发性骨髓瘤,约36%的患者是近两年内诊断的(2019-2020年),54%的患者正在接受一线治疗。

患者的来源、死亡率及相关风险因素

33%的患者已死亡,具有显著地域差异,住院患者的死亡率波动在27%-57%不等。单变量分析发现,年龄、国际分期系统3期(ISS3)、高危疾病、肾脏疾病、骨髓瘤控制不佳(活动性或进展性疾病)以及1种或1种以上合并症是较高死亡率的危险因素

无论是移植史,包括新冠肺炎确诊后一年内的移植史,还是其他抗MM治疗,都与预后无关。多变量分析发现,只有年龄、高危型MM、肾脏疾病和MM控制不佳仍是新冠肺炎感染不良预后的独立预测因素。

总而言之,在新冠肺炎病毒大流行的当下,多发性骨髓瘤的管理需仔细考虑患者和疾病相关因素,以降低感染新冠肺炎病毒的风险,同时进行适当的治疗而不相互影响疾病控制效果。该研究为感染新冠肺炎的多发性骨髓瘤患者的治疗提供了初步建议。

原始出处:

Chari Ajai,Samur Mehmet Kemal,Martinez-Lopez Joaquin et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 2020, 136: 3033-3040.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890200, encodeId=f6b91890200a4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 24 05:23:43 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948389, encodeId=61b71948389d0, content=<a href='/topic/show?id=a646e252819' target=_blank style='color:#2F92EE;'>#相关危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72528, encryptionId=a646e252819, topicName=相关危险因素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Sat Feb 06 12:23:43 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028928, encodeId=fb1f1028928b7, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 31 00:23:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912325, encodeId=2fa4912325ab, content=第一次发现这个软件,感觉很多东西要去学习 , beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Wed Dec 30 21:43:35 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2021-07-24 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890200, encodeId=f6b91890200a4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 24 05:23:43 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948389, encodeId=61b71948389d0, content=<a href='/topic/show?id=a646e252819' target=_blank style='color:#2F92EE;'>#相关危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72528, encryptionId=a646e252819, topicName=相关危险因素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Sat Feb 06 12:23:43 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028928, encodeId=fb1f1028928b7, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 31 00:23:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912325, encodeId=2fa4912325ab, content=第一次发现这个软件,感觉很多东西要去学习 , beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Wed Dec 30 21:43:35 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890200, encodeId=f6b91890200a4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 24 05:23:43 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948389, encodeId=61b71948389d0, content=<a href='/topic/show?id=a646e252819' target=_blank style='color:#2F92EE;'>#相关危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72528, encryptionId=a646e252819, topicName=相关危险因素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Sat Feb 06 12:23:43 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028928, encodeId=fb1f1028928b7, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 31 00:23:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912325, encodeId=2fa4912325ab, content=第一次发现这个软件,感觉很多东西要去学习 , beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Wed Dec 30 21:43:35 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2020-12-31 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1890200, encodeId=f6b91890200a4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 24 05:23:43 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948389, encodeId=61b71948389d0, content=<a href='/topic/show?id=a646e252819' target=_blank style='color:#2F92EE;'>#相关危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72528, encryptionId=a646e252819, topicName=相关危险因素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uiafWKNzZJdibyrrAR5YyVBUCbj0fhAekic1Tou5YEI9IBoJ1QrGpZylYAkiafDNofZkNHJCPTpY1HK14LvuFzD5xQ/132, createdBy=706e2500208, createdName=ms9203727104890838, createdTime=Sat Feb 06 12:23:43 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028928, encodeId=fb1f1028928b7, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Dec 31 00:23:43 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912325, encodeId=2fa4912325ab, content=第一次发现这个软件,感觉很多东西要去学习 , beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Wed Dec 30 21:43:35 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2020-12-30 ms7000000261672610

    第一次发现这个软件,感觉很多东西要去学习

    0

相关资讯

骨髓瘤治疗新进展,全新作用机制药物Selinexor(ATG-010)三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南

12月15日,德琪医药有限公司(简称“德琪医药”)宣布,美国国家综合癌症网络(NCCN®)在最新版多发性骨髓瘤临床实践指南(NCCN Guidelines®)中添加了三种selinexor(ATG-0

Br J Haematol:来那度胺治疗失败后,复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗

复发/难治性多发性骨髓瘤(RRMM)患者在早期治疗线中已经用尽了来那度胺的优势,迫切需要有效的治疗方法。在2期MM-014试验的队列A中,研究人员考察了来那度胺治疗失败后立即加低剂量地塞米松对RRMM

Br J Cancer:逆转多发性骨髓瘤耐药性的替代策略

蛋白酶体抑制剂(PIs)能够显著提高多发性骨髓瘤(MM)的治疗反应并改善患者的生存率。然而,在PI治疗过程中的耐药性的产生仍是该疾病治疗过程中的主要障碍。

FDA批准Karyopharm的Xpovio(selinexor)用于治疗多发性骨髓瘤

FDA已批准Xpovio(selinexor)联合硼替佐米和地塞米松用于治疗多发性骨髓瘤成年患者,这些患者至少接受过一种疗法。

Blood:与多发性骨髓瘤患者感染新冠病毒预后的相关因素

多发性骨髓瘤(MM)患者发病和死亡的主要原因是感染。因此,在COVID-19大流行期间,人们都非常关注感染COVID-19的MM患者的预后。

Oncopeptides发表多发性骨髓瘤Ⅱ期ANCHOR联合研究的新数据

美洛芬加地塞米松联合达拉妥单抗或硼替佐米的三联疗法对复发性难治性多发骨髓瘤患者的治疗表现出令人鼓舞的活性、良好的耐受性以及与使用时相似的安全性